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An uneven landscape: Geographic disparities in cancer burden and 
underlying factors
Studies have shown time after time that where people live can affect what diseases they get, 
how they die, and when they die (1–6). In 2017, about fifteen percent of the U.S. population
—about 46 million people—lived in rural areas. While geography alone cannot predict 
cancer risk, it can impact prevention, screening, diagnosis, and treatment opportunities. The 
articles in this special CEBP Focus issue on rural cancer control explore geographic 
disparities across the cancer control continuum in several distinct rural communities and 
map out potential paths to reach geographic health equity (7–12).
Cancers of the female breast, prostate, lung, and colorectal cancers are the most common 
cancers in the United States, in both rural and metropolitan areas (6). However, people who 
live in rural areas, compared with people who live in metropolitan areas, tend to have lower 
incidence rates for several cancer types that could be detected through screening and 
diagnostic imaging services (e.g., female breast, prostate, thyroid, and kidney cancers), but 
higher incidence rates for smoking-related cancers (e.g., lung and bladder cancer) and 
human papillomavirus (HPV)-related cancers (e.g., cervix cancer). Death rates are higher in 
persons residing in rural than metropolitan areas for many cancer types, particularly those 
amenable to primary prevention (e.g., lung cancer, Figure 1A and cervical cancer, Figure 
1B), screening and early detection (e.g., colorectal cancer; Figure 1C), quality cancer 
treatment and cancer survivorship care (e.g., prostate cancer, Figure 1D). Moreover, progress 
in reducing cancer death rates for all cancers combined and for most common cancers has 
been slower in rural than in urban areas, further widening the disparity in mortality (Figure 
2).
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Factors contributing to slower progress and higher burden of cancer in rural areas are multi-
factorial and include economic, social, and structural barriers. Persons residing in rural areas 
were more likely to live below the Federal poverty level (16%) than those residing in 
metropolitan areas (12%) and less likely to have medical insurance (13% vs 10%; Figure 
3A) (13), potentially limiting access to recommended preventive, early detection, and 
treatment services (14–16). Prevalence of cigarette smoking, obesity, and physical inactivity, 
common risk factors for many cancer types (17), were higher among residents of rural areas 
than among residents of metropolitan areas (Figure 3B) (13, 18). Comprehensive tobacco 
prevention and control programs are proven to reduce smoking prevalence (19, 20); 
however; tobacco control efforts such as smokefree policies, excise taxes on tobacco 
products, and accessibility to smoking cessation resources tend to be lower in rural areas 
compared with metropolitan areas (13). Vaccination uptake rates for human papillomavirus 
(HPV) among adolescent boys and girls were lower in rural areas than in metropolitan areas, 
potentially impacting future cancer burden, (Figure 3C) (21) despite the availability of the 
vaccine to children to low-income families at no cost through a Federal program, Vaccines 
for Children (22). However, vaccination rates for hepatitis B virus among children were high 
(>90%) in both rural and metropolitan areas (Figure 3C), suggesting that barriers other than 
cost may impact low HPV vaccination rates. According to data from the 2015 National 
Health Interview Survey the prevalence of receiving recommended screening tests for 
female breast, colon and rectum, and cervical cancers (Figure 3D) were lower in persons 
residing in rural areas than among residents of metropolitan areas (13). Lower adherence to 
screening could be due to factors such as barriers to transportation to screening facilities, 
unaffordable screening tests, insufficient number of local screening facilities, or shortage of 
trained personnel, such as radiologists (6, 23). Persons residing in rural areas may be less 
likely to receive guideline concordant treatments. For example, receipt of radiation therapy 
for breast cancer patients residing in the National Cancer Institute’s Surveillance, 
Epidemiology and End Results program was lower for rural (62.1%) than urban (69.1%) 
patients (24). There are fewer primary healthcare providers and specialists in rural areas 
which may limit access to timely and high-quality prevention, early detection, treatment, and 
survivorship care services.
Bridging the gap: Stories from the field
In this special CEBP Focus issue, six papers share new insights into cancer disparities in 
rural communities. A paper by Zahnd et al. examines cancer incidence rates and trends by 
demographic, geographic, and socioeconomic characteristics based on a multistate database, 
covering 93% of the US population, and confirms that cancer rates associated with 
modifiable risks, such as tobacco use and HPV infection, and some preventive screening 
modalities were higher in rural areas compared with urban areas (7). Zahnd and colleagues 
underscore the utility of such large and generalizable databases for monitoring the cancer 
burden in rural communities and other under-served populations to inform further research 
and public health efforts. Ross and colleagues examined progress in reducing lung cancer 
death rates among women from 1990 to 2015 by county, and found that while lung cancer 
death rates steadily decreased in most counties, they increased until the late 2000s in several 
rural counties in Appalachia and the Midwest, widening geographic inequities in lung cancer 
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mortality (8). The authors noted that these geographic areas are characterized by weak 
tobacco control policies such as low excise tax on cigarettes and lack of comprehensive 
smoke-free policies banning smoking in all workplaces, restaurants and bars, and called for 
intensifying local tobacco control policies.
Paskett et al conducted a-year long church-based diet and exercise intervention trial with 
input from the community to reduce obesity in Appalachia (9). The authors found that 
participants who actively participated and attended more education sessions about physical 
activity and healthy diet were more likely to lose weight. However, the authors reported that 
only a third of participants regularly attended educational sessions and noted the need for 
more in-person contact to increase the impact of the intervention. Nevertheless, this trial 
demonstrates the importance of social gatherings such as churches as a vehicle to motivate 
healthy behaviors in rural and other underserved communities. Briant and colleagues 
showcased the benefits of using culturally tailored interventions to improve health 
awareness, knowledge, and behavior; their study showed that promotor(a)-led “home health 
parties” increased the use of fecal occult blood test screening from 51% to 80% among 
Hispanic men and women living in rural Washington State (10). McDougall et al studied 
colorectal cancer survivors in New Mexico and found that those who lived in rural areas 
were more likely to experience financial hardship and less likely to adhere to recommended 
follow-up care, highlighting the importance that place plays in affordable, accessible 
survivorship care (11). To examine the associations of neighborhood characteristics in 
Missouri with treatment and outcomes of ductal carcinoma in situ, Zhang, Liu and 
colleagues used census tract level socioeconomic deprivation and rural-urban commuting 
area codes to define rurality; while differences in treatment, but not outcome, were found, 
the authors suggest that larger studies using nuanced definitions of rurality are needed to 
refine our understanding the contribution of place to outcome (12). It is noteworthy that the 
definition, location, and composition of “rural” differ across the United States and these may 
affect the interpretation of the study findings included in this special issue.
Conclusion
The papers in this special issue describe disparities in cancer risk, screening, treatment, and 
outcome that exist in several different rural populations, confirming that not all communities 
in the United States have benefitted from advances in cancer prevention and control. These 
papers also describe novel approaches to promote physical activity, healthy eating habits, 
and CRC screening in rural areas through community participation, which could inform 
future studies and public health efforts to promote healthy behaviors and environments. 
Bridging the chasm in geographic health inequity requires such targeted, culturally 
appropriate, and sustainable interventions to improve access to primary prevention, early 
detection, and treatment services (23).
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Figure 1. 
Healthy People 2020 objectives for cancer and average annual death rates (per 100,000 
persons, age-adjusted to the 2000 U.S. standard population) from selected cancers (A. Lung 
Cancer, B. Cervical Cancer, C. Colorectal Cancer, D. Prostate Cancer) by county 
classification—United States, 2011–2015. Healthy People 2020 objectives for cancer death 
rates are indicated with a dotted line (Reference 13). Counties were identified using the 
United States Department of Agriculture Economic Research Service 2013 vintage rural-
urban continuum code, which categorizes nonmetropolitan counties by degree of 
urbanization and adjacency to a metro area, and metropolitan counties by the population size 
of their metro area (https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/). 
(Adapted from Reference 6).
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Figure 2. 
Trends in cancer death rates (per 100,000 persons, age-adjusted to the 2000 U.S. standard 
population) from 2006 to 2015 in U.S. rural (nonmetropolitan) and metropolitan counties. 
The Healthy People 2020 objective for cancer death rate is indicated with a dotted line 
(Reference 13). Average annual percent change (AAPC) in rates calculated using joinpoint 
regression was used to describe trends. (Adapted from Reference 6)
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Figure 3. 
Healthy People 2020 objectives related to cancer, including social determinants of health, 
health risk behaviors, recommended vaccination against cancer-causing viruses, and 
recommended cancer screening. Data for most indicators are from the 2015 or 2016 
National Health Interview Surveys reported in the Healthy People 2020 database (Reference 
13); data for poverty are from the 2016 Current Population Survey (Reference 13); data for 
obesity prevalence are from the 2016 Behavioral Risk Factor Surveillance System 
(Reference 18) and data for vaccination rates are from the 2015 National Immunization 
Survey (Reference 21).
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